Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syngene International Ltd. ( (IN:SYNGENE) ) just unveiled an update.
Syngene International has extended and expanded its long-term strategic research collaboration with Bristol Myers Squibb through 2035, broadening the scope of integrated services from early discovery through development, manufacturing and clinical support to commercialization. The renewed agreement deepens a partnership that began in 1998 and centers on the Biocon Bristol Myers Squibb Research and Development Center in Bengaluru, where around 700 Syngene scientists operate as an extension of BMS’s global research organization, strengthening Syngene’s role as a critical R&D and manufacturing hub for key therapeutic areas and reinforcing its position as a leading end-to-end CRDMO partner to large pharma.
More about Syngene International Ltd.
Syngene International Ltd. is a global contract research, development and manufacturing organization (CRDMO) based in India, providing integrated scientific and manufacturing services across the drug development lifecycle. Its offerings span discovery chemistry and biology, drug metabolism and pharmacokinetics, translational sciences, pharmaceutical development, manufacturing, clinical trial support, and data and IT services for global biopharmaceutical clients, positioning the company as a long-term strategic partner in outsourced R&D and development programs.
Average Trading Volume: 44,764
Technical Sentiment Signal: Sell
Current Market Cap: 252.7B INR
For detailed information about SYNGENE stock, go to TipRanks’ Stock Analysis page.